Global E Online Ltd vs Vaxcyte Inc. Common Stock — how do they compare? Global E Online Ltd trades at $38.28 (market cap $6.55B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is more actively traded (2,644,694 versus 1,171,020). Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| GLBE | PCVX | |
|---|---|---|
Market Cap | $6.55B | $10.51B |
Volume | 1,171,020 | 2,644,694 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $73.82 |
52-Week Low | $27.54 | $40.32 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $6.05B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $39.00, down 0.05% with a bearish technical signal. The company shows strong fundamentals with Q2 2026 earnings beating expectations and revenue growth accelerating to 39% year-over-year. Analyst sentiment remains overwhelmingly positive with 93% buy ratings and a $48.86 consensus price target representing 25% upside potential. Recent executive appointments and strong Q2 results have driven positive momentum, though insider selling activity warrants monitoring.
The outlook remains favorable with projected revenue growth to $1.1B in 2026 and expanding profit margins. Key risks include competitive pressures in e-commerce enablement and potential market volatility. The stock's current valuation at 44.32 P/E reflects growth expectations, with technical resistance at $40 needing to be overcome for further upside.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →